Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Blood (2020) 136 (23): 2628–2637.

https://doi.org/10.1182/blood.2020005588

Published: 2020

Includes: Supplemental data

Journal Articles

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Giuseppe Gritti, MD PhD, Paula Marlton, MBBS FRACP FRCPA, Tycel J. Phillips, MD, Christopher Arthur, Rajat Bannerji, MDPhD, Paolo Corradini, Anna Johnston, John F. Seymour, Sam Yuen, MBBS, FRACP, FRCPA, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers, MDMS

Blood (2020) 136 (Supplement 1): 45–47.

https://doi.org/10.1182/blood-2020-136361

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Stephen R Larsen, MBBS PhDFRACP FRCPA, Andrew Spencer, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Simon Durrant, MBBS FRCP FRCPath, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Hugh J. Goodman, FRACP, Ian H. Kerridge, FRACP FRCPA MPhil BA, Christopher Arthur, Cameron Curley, MBBS, FRACP, FRCPA, Caroline Stewart, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Jennifer Collins, Julian Cooney, FRACP,FRCPA,MBBS,, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139076

Published: 2020

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma

David Simon Kliman, MBBS, Louise Imlay-Gillespie, BMed, Kirsten McIlroy, MBBS, FRCPA, Anthony Gill, MBBS, MD FRCPA, Christopher Arthur, MBBS, FRACP, FRCPA, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB, FRACP, FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William S Stevenson, MBBS, PhD FRACP, FRCPA, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 2656.

https://doi.org/10.1182/blood.V126.23.2656.2656

Published: 2015

Journal Articles

Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study

Louise Imlay-Gillespie, BMed, Caroline Dix, MBBS, Ashley McEwan, MD, Kelly Wong, Melanie Figtree, MBBS, Christopher Arthur, MD, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William Stevenson, MBBS, PhD, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA

Blood (2015) 126 (23): 2108.

https://doi.org/10.1182/blood.V126.23.2108.2108

Published: 2015

Journal Articles

Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders

Louise Imlay-Gillespie, BMed, David Simon Kliman, MBBS, Kelly Wong, Christopher Arthur, MD, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB FRACP FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William Stevenson, MBBS, PhD, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 5038.

https://doi.org/10.1182/blood.V126.23.5038.5038

Published: 2015

Journal Articles

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, David T. Yeung, Phuong Dang, Jarrad M. Goyne, Cassandra Slader, Robin J. Filshie, Anthony K. Mills, Junia V. Melo, Deborah L. White, Andrew P. Grigg, Timothy P. Hughes

Blood (2013) 122 (4): 515–522.

https://doi.org/10.1182/blood-2013-02-483750

Published: 2013

Includes: Supplemental data

Journal Articles

A Post Hoc Landmark Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Xavier Thomas, MD, Christopher Arthur, MD, Jacques Delaunay, MD, Mark M Jones, MD, Erhan Barrak, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 3623.

https://doi.org/10.1182/blood.V120.21.3623.3623

Published: 2012

Journal Articles

Progress Findings On a Novel Treatment Strategy Using Prolonged, Low-Dose Cytarabine and Thioguanine in Combination with Peg-Filgrastim for Acute Myeloid Leukaemia in Elderly Patients

Christopher Arthur, Charmaine Wong, MB BS, Brandon Aubrey, MB BS, Eunice Liu, MB BS, William Stevenson, MBBS, PhD, Gary Soo, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB, Matthew Greenwood, MD, FRACP, FRCPA, Naomi Mackinlay, MB BS FRACP FRCPA, Christopher M Ward, MB, PhD

Blood (2012) 120 (21): 3612.

https://doi.org/10.1182/blood.V120.21.3612.3612

Published: 2012

Journal Articles

Multivariate and Subgroup Analyses of a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Jiri Mayer, M.D., PhD., Prof., Christopher Arthur, MD, Jacques Delaunay, MD, Grzegorz Mazur, MD, PhD, Xavier Thomas, MD, Agnieszka Wierzbowska, MD, PhD, Mark M Jones, MD, Erhan Berrak, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 3618.

https://doi.org/10.1182/blood.V120.21.3618.3618

Published: 2012

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

Journal Articles

Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.

Michael P Osborn, Deborah L White, PhD, Verity A Saunders, Bronwyn Cambareri, Susan Branford, PhD, Andrew Menelaou, Bereha Khodr, PhD, Cassandra Slader, Mark Hertzberg, Anthony Schwarer, David Ma, MD, Christopher Arthur, Cecily J. Forsyth, Samar Issa, Yiu Lam Kwan, John Taper, Andrew Grigg, Timothy P. Hughes, MD

Blood (2009) 114 (22): 1131.

https://doi.org/10.1182/blood.V114.22.1131.1131

Published: 2009

Journal Articles

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Davi D M Ross, Andrew Grigg, Anthony Schwarer, Christopher Arthur, Kerryn Loftus, Anthony K Mills, Robin Filshie, Ruth Columbus, John Reynolds, John F Seymour, MB, BS, PhD, FRACP, Susan Branford, Timothy Hughes

Blood (2008) 112 (11): 1102.

https://doi.org/10.1182/blood.V112.11.1102.1102

Published: 2008

Journal Articles

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

Susan Branford, Rebecca Lawrence, Andrew Grigg, John Francis Seymour, MBBS, Anthony Schwarer, Christopher Arthur, Zbigniew Rudzki, Timothy Hughes

Blood (2008) 112 (11): 2113.

https://doi.org/10.1182/blood.V112.11.2113.2113

Published: 2008

Journal Articles

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine

Blood (2005) 105 (2): 481–488.

https://doi.org/10.1182/blood-2004-01-0326

Published: 2005

Journal Articles

A Stratified Risk-Adapted Approach to Lymphoma Salvage in an Outpatient Setting.

Andrew Spencer, DM, John Catalano, FRACP, Andrew Grigg, FRACP, Michael Leahy, FRACP, Craig Underhill, FRACP, Vinod Ganju, FRACP, Christopher Arthur, FRACP

Blood (2004) 104 (11): 4597.

https://doi.org/10.1182/blood.V104.11.4597.4597

Published: 2004

Journal Articles

Effective Treatment of Elderly Acute Myeloid Leukaemia (AML) with Continuous Combined Granulocyte Colony Stimulating Factor (G-CSF) and Single Oral Chemotherapeutic Agents.

Jennifer L. Curnow, MBBS, Francesco Piccolo, MBBS, Christopher M. Ward, PhD, MBBS, BMedSci, Luke Coyle, MBBS, Keith Fay, MBBS, Naomi Mackinlay, MBBS, Sundra Ramanathan, MBBS, Christopher Arthur, MBBS

Blood (2004) 104 (11): 4515.

https://doi.org/10.1182/blood.V104.11.4515.4515

Published: 2004

NARROW

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma

Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study

Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

A Post Hoc Landmark Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Progress Findings On a Novel Treatment Strategy Using Prolonged, Low-Dose Cytarabine and Thioguanine in Combination with Peg-Filgrastim for Acute Myeloid Leukaemia in Elderly Patients

Multivariate and Subgroup Analyses of a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine

A Stratified Risk-Adapted Approach to Lymphoma Salvage in an Outpatient Setting.

Effective Treatment of Elderly Acute Myeloid Leukaemia (AML) with Continuous Combined Granulocyte Colony Stimulating Factor (G-CSF) and Single Oral Chemotherapeutic Agents.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only